Objectives The aim of this paper was to critically review the literature on the cost effectiveness of cancer screening interventions, and examine the incremental cost-effectiveness ratios (ICERs) that may influence government recommendations on cancer screening strategies and funding for mass implementation in the Hong Kong healthcare system. Methods We conducted a literature review of cost-effectiveness studies in the Hong Kong population related to cancer screening published up to 2015, through a hand search and database search of PubMed, Web of Science, Embase, and OVID Medline. Binary data on the government's decisions were obtained from the Cancer Expert Working Group, Department of Health. Mixed-effect logistic regression analysis was used to examine the impact of ICERs on decision making. Using Youden's index, an optimal ICER threshold value for positive decisions was examined by area under receiver operating characteristic curve (AUC). Results Eight studies reporting 30 cost-effectiveness pairwise comparisons of population-based cancer screening were identified. Most studies reported an ICER for a cancer screening strategy versus a comparator with outcomes in terms of cost per life-years (55.6 %), or cost per qualityadjusted life-years (55.6 %). Among comparisons with a mean ICER of US$102,931 (range 800-715,137), the increase in ICER value by 1000 was associated with decreased odds (odds ratio 0.990, 0.981-0.999; p = 0.033) of a positive recommendation. An optimal ICER value of US$61,600 per effectiveness unit yielded a high sensitivity of 90 % and specificity of 85 % for a positive recommendation. A lower ICER threshold value of below US$8044 per effectiveness unit was detected for a positive funding decision. Conclusions Linking published evidence to Government recommendations and practice on cancer screening, ICERs influence decisions on the adoption of health technologies in Hong Kong. The potential ICER threshold for recommendation in Hong Kong may be higher than those of developed countries.
Introduction
Owing to the rapid development and increasing cost of health interventions, the health economic evaluation is an essential approach to critically appraise the costs and benefits of new health interventions. Because of limited healthcare resources, the integration of an emerging health intervention into a healthcare system has to be well articulated with scientific justifications. From the perspective of a health policy maker, the emerging health intervention not only has to be more effective than the conventional interventions, but also good value for money.
A health economic evaluation is a scientific process of review and assessment. Emerging health interventions in Western countries are primarily assessed by a single advisory body, for example, the National Institute for Health and Care Excellence (NICE) [1] in the United Kingdom (UK), the Pharmaceutical Benefits Advisory Committee (PBAC) in Australia, the Canadian Agency for Drugs and Technologies in Health (CADTH) in Canada, and the Pharmaceutical Management Agency (PHAR-MAC) in New Zealand. Such advisory bodies in their respective countries often monitor the effectiveness and cost effectiveness of emerging interventions in healthcare, and therefore provide national guidance and recommendations on the decision of whether the health intervention is to be accepted or rejected for implementation in routine clinical practice. The incremental cost-effectiveness ratio (ICER) of a new intervention relative to the conventional intervention against the country-specific threshold value is a critical determinant for decision making, while other practical considerations including budgeting and ethical issues are also taken into account.
In Hong Kong, evaluations and recommendations on publically funded health interventions are not the responsibility of a single advisory body but different committees, depending upon the nature of the interventions. The Drug Advisory Committee of the Hospital Authority [2] has the role of recommending pharmaceutical interventions in the Hospital Authority. Existing and new pharmaceutical interventions approved by the Drug Advisory Committee are included in the Hospital Authority Drug Formulary [3] , which was initiated in 2005. Drugs on the formulary list are classified as general drugs with full government subsidy, special drugs with certain charges, and self-financing drugs. The health technology assessment process is subject to challenge for a lack of transparency to the general public and a lack of documentation of the scientific basis for decision making [4] . Different committees were set up to review scientific evidence and offer recommendations for the prevention of communicable and non-communicable diseases. In the field of cancer screening interventions, the Cancer Expert Working Group (CEWG) [5] , under the Cancer Coordinating Committee, provides recommendations on suitable cancer prevention and screening measures at the population level.
There is a growing body of health economic analyses evaluating health interventions utilized in the public sector of health services in Hong Kong and that were thereby compared with the ICER thresholds from other countries to inform decision making. However, the ICER thresholds adopted for comparison are rather diverse. Studies in the UK adopted the threshold cost of £20,000-£30,000 per quality-adjusted life year (QALY) gained, suggested by NICE [1] , whereas studies in the United States (US) adopted the benchmark of US$50,000 per life-year or per QALY gain, suggested by a cost-effectiveness analysis of a hospital renal dialysis study in 1992 [6] . Countries are recommended to set their own ICER threshold to reflect how much they value the gain in health of their populations, and to achieve appropriate drug pricing [7] . Although developed countries like the UK have adopted ICER thresholds, the ideal or widely accepted ICER threshold has yet to be established in Hong Kong or in mainland China by extension. One particular method [8] for threshold estimation is to infer the value of an ICER threshold from the previous decisions, such that the relationship between the decision and ICER values of previous health interventions was applied to measure an overall threshold value over the past decision-making processes. An alternative approach of setting the ICER threshold at three times the national gross domestic product (GDP) per capita was recommended by the World Health Organization (WHO) [9] . However, no prior studies have been conducted to establish such a relationship. Research on the appropriate ICER threshold for recommendation and funding in Hong Kong is lacking.
The aims of this study were to explore whether ICER values of cancer screening interventions were associated with decisions on recommending and/or accepting the interventions in Hong Kong, and to estimate the ICER thresholds applied by health policy makers on cancer screening in Hong Kong.
Methods

Literature Search on Health Technology
Assessment in Hong Kong
Search Engines and Strategies
A systematic literature search was conducted in the databases of PubMed, Web of Science using the Web of Knowledge platform, Embase, and MEDLINE using the Ovid searching platform to identify studies that investigated the economic evaluation of health interventions to be considered in the public clinical setting in Hong Kong. The Medical Subject Headings 'Hong Kong', 'China', and 'Chinese' were combined with 'cost-effectiveness', 'costeffective', 'cost-benefit', 'cost-utility', 'cost-minimization', 'cost-minimisation', 'cost-saving', 'willingness-topay' and 'economic evaluation' (Appendix 1, see electronic supplementary material). Studies were limited to the English language, and publication years between 1990 and 2015. The earliest year was chosen as 1990 because the concept of value for money in health emerged around the early 1990s [10] . An additional hand search of the Google search engine was conducted to include recent studies published in 2015 and past evidence from commissioned and non-commissioned reports to the Food and Health Bureau, in case those reports were publicly available. If there were duplicated articles or reports, the most complete work done by the authors was selected. After the initial check for duplicated articles, abstracts of the remaining articles were screened by two authors (CW and BL) to exclude editorials, letters, commentaries, study protocols, case reports, pure literature reviews and meta-analyses, conference proceedings, past and current clinical guidelines, and recommendations.
Inclusion and Exclusion Criteria
After reviewing the full text of screened articles, the eligibility criteria of studies were (1) to involve the economic evaluation of cancer screening strategies with the status quo as the comparator, and (2) to evaluate the ICER of one screening strategy relative to the comparator. Articles with no available full text or full report were excluded. Methodological quality of the included studies was assessed according to the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement [11] , which was adopted as the evaluation of reporting standards of health economics analyses. Articles that lack transparency and reporting of three essential items (target population and subgroups, comparators, and measurement of effectiveness) were further excluded from subsequent analyses.
Data Extraction
A standardized form was used when extracting the data reported in included studies. 
Past Decisions from Government
Recommendations made by the Cancer Expert Working Group (CEWG) on Cancer Prevention and Screening, Department of Health [5] were referred to the published clinical practice guidelines and recommendation report.
As of the date of searching (January 2016), using the latest available data, a decision of non-recommendation was assumed if the particular screening had not yet been considered or recommended by the committee. The final decision of recommendation was recorded as binary outcomes of 'recommended'/'not recommended'. A decision of non-funding was assumed if the particular screening implemented in the targeted population group was not yet supported by the Department of Health and government bureau. Two mass cancer screening programs have been officially recommended by the Department of Health. Since 2004, CEWG has recommended regular pap smear screening [5] and implemented a cervical screening program. Furthermore, CEWG recommended individuals aged 50-75 years consider colorectal cancer screening by fecal occult blood test every 1-2 years, sigmoidoscopy every 5 years or colonoscopy every 10 years [5] , and will thus implement the Colorectal Cancer Screening Pilot Programme in the second half of 2016 [12] .
Statistical Analysis
In retrospective analysis, effects of the ICER on decisions (recommendation and/or funding) were tested by mixedeffect logistic regression models with the adjustment of multiple comparative cost-effectiveness analyses reported in each study. The equation for the logistic regression model was specified as
where Y is the dichotomous outcome variable, decision making; ICER is the continuous independent variable, ICER value; b 0 and b 1 are fixed-effect regression coefficients of intercept and ICER value, respectively; STUDY is the random-effect covariate; c is the random intercept at the study level; and e is the error term.
The goodness-of-fit of the model was assessed using a log likelihood value and Wald v 2 test. An odds ratio (OR) of ICER \1 indicated that the decrease in ICER was associated with higher odds of a recommendation or acceptance for funding than a negative decision. The predicted probability of recommendation or acceptance for funding was calculated for each ICER value. A sensitivity analysis was performed on the cost-effectiveness comparisons reporting ICER values in terms of cost per QALYs gained or cost per DALY averted, which incorporated both the quantity and quality of life in the effectiveness unit.
The performance of each threshold cut-off value for a positive decision in terms of sensitivities and specificities was calculated. Sensitivity and specificity were defined as the probability of a positive decision given the condition that the ICER value was less than the threshold cut-off value, and the probability of a negative decision provided that the ICER value was greater than the threshold cut-off value. Youden's index is the sum of sensitivity and specificity minus one while the maximum value of Youden's index was used for identification of an optimal ICER threshold value for a positive decision. The receiver operating characteristic (ROC) curve was obtained by plotting sensitivity against one minus specificity for each ICER cut-off value. Discrimination of the ICER value was examined by area under the ROC curve (AUC).
All statistical analyses were performed using STATA Version 13.0 (StataCorp LP, College Station, TX, USA). All significance tests were two-tailed and those with a p value \0.05 were considered statistically significant. Figure 1 shows the process of literature identification, abstract screening for eligibility, and selection of original studies during the literature and hand search, presented in a PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram [13] . A systematic database search of four research databases was completed in March 2015 and identified a total of 1335 potentially relevant studies (PubMed 446; Web of Science 232; MEDLINE 300; and Embase 357) that met the search criteria. After the removal of duplicated articles (n = 544), non-original articles (n = 237), and other non-relevant articles (n = 484) by abstract screening, the full text of 70 studies were assessed for eligibility. Of these, 64 were not related to cancer screening and one did not report ICER values, and was considered to be of poor methodological quality. After the addition of four eligible studies found through hand searching, nine [14] [15] [16] [17] [18] [19] [20] [21] [22] cost-effectiveness studies related to cancer screening were finally included in this review. The earliest study [14] that assessed comparative cost effectiveness of cancer screening was published in 2004. Table 1 summarizes the characteristics of studies included in this review. We identified four (44.4 %) costeffectiveness analyses and five (55.6 %) cost-utility analyses in which QALYs were used as the effectiveness unit for the ICER value. Studies evaluated cancer screening strategies designed for a wide range of disease populations including colorectal cancer (33.3 %), cervical cancer (22.2 %), and breast cancer (22.2 %). Clinical data were mostly sourced from purely published literature (66.7 %) and cross-sectional data combined with literature data (22.2 %). Most studies established a Markov model (88.9 %), evaluated from the perspective of the healthcare provider (77.8 %), and reported an ICER of a cancer screening strategy versus the comparator as outcomes in terms of cost per life-years (55.6 %), or cost per QALYs (55.6 %). One study that reported the 'cancer cases detected' as the effectiveness unit of ICER value was not considered in the retrospective analysis.
Results
The retrospective analysis included eight studies that have reported 30 cost-effectiveness pairwise comparisons of population-based cancer screening for colorectal (n = 16, 53.3 %), cervical (n = 9, 30 %), breast (n = 4, 13.3 %), and gastric cancers (n = 1, 3.3 %). General characteristics of the 30 pairwise comparisons and their respective decisions are shown in Table 2 . Of the 30 pairwise comparisons analyzed, 20 (66.7 %) received a positive recommendation for implementation by CEWG, and 15 (50 %) were accepted by Government for routine use at the time of analysis. Seven comparisons reported in three studies expressed an ICER value in terms of both cost per life-year gained and cost per QALY gained, of which the latter was used in the retrospective analysis. No strategies were deemed to be cost-saving, leading to a negative ICER value, relative to comparator. Table 3 shows the effects of the ICER value on past decision making on cancer screening strategies in retrospective analyses. Among comparisons with a mean ICER of US$102,931 (median 19,166; range 800-715,137), the mean ICER value was four times higher for non-recommended cancer screening strategies than for those that were recommended by CEWG (US$222,837 vs. US$42,978).
Similarly, for acceptance of strategies for funding for routine use, the mean ICER for non-acceptance was 2.5-fold higher than that for acceptance (US$160,766 vs. US$45,096). Mixed-effect logistic regression models depicted that an increase in ICER value by US$1000 was associated with decreased odds (OR 0.990, 0.981-0.999; p = 0.033) of a positive recommendation. The ICER at which the predicted probability of a positive recommendation was 50 % was between US$134,685 and US$195,209. Although there is no significant association between the ICER value and funding decision for routine use, the predicted probability of the funding decision varied with the ICER value. The ICER at which the cancer screening had a 50 % chance of funding was between US$72,534 and US$134,685. Figure 2 displays the impact of the ICER value on the predicted probabilities of a positive decision that accepted the strategy for recommendation and funding. A sensitivity analysis using the costeffectiveness comparisons reporting ICER value in terms of cost per QALY gained or cost per DALY averted demonstrated an estimated OR of \1 (OR 0.995, 0.987-1.003; p = 0.205), though this was not statistically significant. Based on the Youden's index, an ICER value of below US$61,600 per effectiveness unit yielded a high sensitivity of 90 % and specificity of 85 % for a positive recommendation. A lower ICER threshold value of below US$8044 was detected for a positive funding decision, with a sensitivity of 86.7 % and a specificity of 73.3 %. The ICER value yielded excellent discrimination for recommendation and funding, with an AUC of 0.890 (95 % CI 0.770-1.000) and 0.822 (95 % CI 0.656-0.988), respectively. Figure 3 demonstrates the ROC curve and the optimal ICER threshold value for a positive decision.
Discussion
The health technology assessment is a standardized process to assess the value of a new healthcare intervention and the ICER value is an important element to be considered in this process. In Hong Kong, the funded health interventions must be recommended by an advisory body but the health interventions recommended by an advisory body are not necessarily funded by the government bureau for implementation. The health technology assessment for recommending cancer screening strategies is conducted by CEWG while the government bureau has the final decision on whether to launch a mass population-based screening program for individuals. This review identified nine published studies consisting of 30 cost-effectiveness comparisons assessing the cost effectiveness of cancer screening interventions relative to status quo in Hong Kong. The small number of cost-effectiveness comparisons identified in this review indicates the limited health economic evidence available on the cancer screening interventions in Hong Kong, indicating a need for further cost-effectiveness analyses of other controversial cancer screening such as ovarian cancer screening, prostate cancer screening, and endometrial cancer screening. The retrospective analysis addressed two objectives: (1) to examine whether the decision making of cancer screening strategies for recommendation or funding in routine clinical practice was based on the ICER value, and (2) to identify the ICER thresholds for previous decisions on cancer screening in Hong Kong. In response to the first objective, findings reflected a significant relationship between the ICER values and the decisions to recommend cancer screening strategies by the CEWG, suggesting that the lower the ICER value of a cancer screening strategy, the greater the odds that it is recommended by CEWG. Therefore, the ICER value may play an important role in decision making during the health technology assessment of cancer screening strategies in Hong Kong. This result is in line with reimbursement decision making in developed countries [23] [24] [25] [26] [27] [28] , emphasizing that the ICER is one of the most influential factors affecting the recommendation of interventions submitted to local advisory bodies during the health technology assessment. Besides health economic evidence, factors related to clinical effectiveness, treatment alternatives, disease severity, and study design of clinical trials are also taken into consideration by the advisory bodies during the health technology assessment [27, 29] .
To address the second objective, an implicit ICER threshold may exist in the Hong Kong context. Our retrospective analyses implied that a threshold for an ICER value of around US$61,600 and US$8044 per one effectiveness unit gained was required to get a positive recommendation and funding decision of cancer screening strategies in Hong Kong, respectively. Interestingly, one gastric cancer screening strategy [18] was not recommended despite the fact that its ICER value (US$17,886) was 2-fold less than the potential ICER threshold value. One plausible explanation of the negative recommendation was in part due to other multiple practical considerations. Previous decision making considers a variety of practical issues including not only health economic evidence but also public acceptance, appropriateness of screening tools for mass population-based screening, and capacity of the healthcare system in coping with screening and positive screening results. The potential ICER threshold for recommendation in the present analysis was slightly higher than the benchmark value in the UK (around £20,000-£30,000 per QALY gained) and the US (US$50,000 per life-year gained). In 2014, the per capita GDP in Hong Kong was around US$40,187 [30] . According to the WHO recommendation suggesting an ICER value of 1-to 3-fold of the per capita GDP to be cost effective [9] , the threshold of the ICER value in the present study fell within the threshold range recommended by WHO; however, the effectiveness unit of the WHO threshold is the DALY, which is not interchangeable with QALYs and life-years gained. Therefore, we recommend increasing efforts to establish an ICER threshold value for decision making in other health interventions such as vaccine and pharmaceutical interventions. However, it is premature to seek an overall cost-effectiveness threshold for positive decisions on healthcare interventions in the Hong Kong healthcare system.
Our synthesized evidence reveals a lack in standardization of reporting of ICER values, year costs of resource units or annual discount rates that conform to the CHEERS checklist. For instance, the presentation of an ICER value was typically expressed in either cost per life-year gained or cost per QALY gained. Only 9 out of 30 (30 %) pairwise comparisons expressed the ICER value in cost per QALY gained (Table 2) , suggesting the need for evidence for preference or utility valuation in cancer health status to enable the QALY calculation. Furthermore, there was a paucity of cost-effectiveness studies alongside a cohort study, or from the societal perspective accounting for indirect costs incurred by patients and their caregivers. Only one study (11.1 %) extrapolated the clinical data from cohort studies to a cost-effectiveness analysis but none of the effectiveness data were sourced from randomized controlled trials. In two studies adopting a societal perspective, indirect costs were incorporated by estimating Fig. 3 Performance characteristics for each incremental cost-effectiveness ratio (ICER) cut-off value using receiver operating characteristic and the optimal ICER threshold value for a positive decision. AUC area under receiver operating characteristic curve patient time including screening time and travel time. In order to present the rationale and evidence to health policy makers and the public, future cost-effectiveness analyses that adopt both the healthcare provider and societal perspectives are required.
Limitations
Discrepancies in the effectiveness unit presented in included studies limited the interpretation of a potential ICER threshold value identified in this review, which adopted the life-year, QALYs or DALYs as effectiveness units. The potential ICER threshold value is interpreted with caution when the ICER value was estimated by other effectiveness units. Secondly, the potential ICER threshold value based on studies between 2004 and 2015 may not reflect the actual value in the future. A temporal effect on the ICER threshold was observed according to UK NICE's decision making, suggesting the inflation of the ICER threshold over time [27] . Thirdly, a health intervention may be recommended and funded with restrictions for use in the European healthcare system. For example, the Scottish health technology assessment can accept the technology for either restricted use or routine use, and reject it for use in NHS Scotland. However, there is no published data on whether the recommended or funded health intervention is under restricted use in Hong Kong. Dependent variables were only coded in a binary fashion, collapsing 'funded with restriction' into the 'funded' decision category. Fourthly, relevant factors influencing decision making and cost-effectiveness analysis were not controlled for in the retrospective analysis. Given the small number of cost-effectiveness comparisons and studies identified in this review, there was a lack of capacity to control for other relevant factors in the retrospective analysis. Finally, the potential ICER threshold value was not generalizable to Chinese in populations other than Hong Kong, and applied to any type of cancer screening in general.
Conclusion
The ICER value may be one of the most important determinants when recommending mass cancer screening interventions by advisory body, but it was not associated with the implementation of population-based screening programs in Hong Kong. Based on a critique of the evidence from cancer screening strategies, we found that ICER value may influence past decisions of health technology assessment in Hong Kong. A potential ICER threshold of US$61,600 per effectiveness unit for what is considered to be a cost-effective intervention for recommendation in Hong Kong was established by this retrospective analysis, which is slighter higher than the benchmark values in developed countries such as the UK and the US, but falls within the range recommended by WHO based on one to three times the annual GDP per capita. However, the potential ICER threshold value for funding decision may be lower than that of developed countries.
